4.7 Article

A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemical Research Methods

Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients

Debbie S. Deben et al.

Summary: Thiopurine derivatives are standard treatments for inflammatory bowel disease, but many patients discontinue therapy within two years. A flow cytometric assay was developed to assess Rac1 and pSTAT3 expression in various leukocyte subpopulations, aiming to predict therapeutic response in IBD patients.

CYTOMETRY PART A (2022)

Review Gastroenterology & Hepatology

Use of thiopurines in inflammatory bowel disease: an update

Arshdeep Singh et al.

Summary: Inflammatory bowel disease (IBD) is now a global disease, with treatment mainly involving biologics and thiopurines, although their use is limited in developing countries. Thiopurines are critical for IBD patients in these regions, but face restrictions in usage.

INTESTINAL RESEARCH (2022)

Article Gastroenterology & Hepatology

The four epidemiological stages in the global evolution of inflammatory bowel disease

Gilaad G. Kaplan et al.

Summary: The global burden of inflammatory bowel disease is evolving into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence, and Prevalence Equilibrium. Developing countries, newly industrialized countries, and Western regions are in different stages of disease evolution.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Review Biochemistry & Molecular Biology

Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease

Debbie S. Deben et al.

Summary: Although conventional thiopurines are commonly used for maintaining remission in inflammatory bowel disease (IBD), therapeutic drug monitoring (TDM) plays an important role in optimizing therapy strategies, despite the debated rationale. TDM of thiopurine metabolites only partially predicts efficacy and toxicity, suggesting the need for additional pharmacodynamic markers in the future.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)

Review Medicine, General & Internal

Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

Carla J. Gargallo-Puyuelo et al.

Summary: Thiopurines play a crucial role in the treatment of IBD, but there are still unresolved issues regarding their efficacy and safety. Personalized therapy based on pharmacogenomics and genetic polymorphisms of metabolizing enzymes may help prevent side effects. Factors such as age, ethnicity, and viral infections also influence the outcomes of thiopurine therapy.

FRONTIERS IN MEDICINE (2021)

Letter Gastroenterology & Hepatology

Value of VAV3 Methylation in Stool DNA Might Be Restricted to Non-Thiopurine-Treated Inflammatory Bowel Disease Patients

Suk Yee Lam et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Review Gastroenterology & Hepatology

Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review

Paulo Gustavo Kotze et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Review Biochemistry & Molecular Biology

Key insights from therapeutic drug monitoring in Crohn's disease patients

Margien L. Seinen et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)

Review Gastroenterology & Hepatology

Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics

Michiel Dirk Voskuil et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Editorial Material Gastroenterology & Hepatology

Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones

Nanne K. H. de Boer

GASTROENTEROLOGY (2019)

Review Pharmacology & Pharmacy

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease

Luc J. J. Derijks et al.

CLINICAL PHARMACOKINETICS (2018)

Editorial Material Gastroenterology & Hepatology

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Joseph D. Feuerstein et al.

GASTROENTEROLOGY (2017)

Review Genetics & Heredity

Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy

Margien L. Seinen et al.

MOLECULAR DIAGNOSIS & THERAPY (2016)

Article Medical Laboratory Technology

Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease

Margien L. Seinen et al.

THERAPEUTIC DRUG MONITORING (2016)

Article Biochemistry & Molecular Biology

MgcRacGAP inhibition stimulates JAK-dependent STAT3 activity

Arjan J. van Adrichem et al.

FEBS LETTERS (2015)

Article Cell Biology

Suppression of p21Rac Signaling and Increased Innate Immunity Mediate Remission in Crohn's Disease

Kaushal Parikh et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

Article Gastroenterology & Hepatology

Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients

Maria Chaparro et al.

INFLAMMATORY BOWEL DISEASES (2013)

Article Gastroenterology & Hepatology

Role of biological therapy for inflammatory bowel disease in developing countries

Gerhard Rogler et al.

Article Gastroenterology & Hepatology

Thiopurine Therapy in Inflammatory Bowel Disease Patients: Analyses of Two 8-Year Intercept Cohorts

B. Jharap et al.

INFLAMMATORY BOWEL DISEASES (2010)

Article Gastroenterology & Hepatology

Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis

J. P. Gisbert et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)

Article Gastroenterology & Hepatology

Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis

James D. Lewis et al.

INFLAMMATORY BOWEL DISEASES (2008)